IonQ's Revenue Soars 755%, But IBM's Quantum Blitz and Insider Selling Curb Enthusiasm

IBM’s pledge to pour $10 billion into quantum computing over five years has reshuffled the deck for pure-play quantum stocks. The blue-chip giant’s announcement, coupled with a $1 billion CHIPS Act grant for its Anderon chip fab in New York, triggered a sharp capital rotation on Monday. IonQ shares slid roughly 4% to around $69, while IBM surged 7% to about $320. Rigetti Computing suffered a similar decline, losing approximately 4% to trade near $24.

The rotation caught IonQ after an extraordinary run. Since April 1, the stock had rallied 128.9%, with a 71% jump in the past month alone — far outpacing the S&P 500’s 14.4% gain over the same stretch. The May 21 announcement of $2 billion in CHIPS Act funds for quantum investments had sent IonQ up 12.25% in a single session, even though the company was not among the nine direct recipients. Atom Computing, Infleqtion, PsiQuantum and Quantinuum were the named beneficiaries.

That exclusion still stings. The Commerce Department allocated $2.013 billion to those nine firms, and Cohen & Company Capital Markets analyst Brandon Sun called IonQ’s absence a potential “comparative disadvantage,” noting that such grants often lead to follow-on government contracts. Market observers estimate a 32% chance that IonQ could be included in a later funding round.

Against that backdrop, IonQ delivered a record quarter. First-quarter 2026 GAAP revenue hit $64.7 million — a 755% leap from a year earlier and 30% above the company’s own midpoint forecast. Remaining performance obligations soared 554% to $470 million. Management raised full-year guidance to a range of $260 million to $270 million.

Should investors sell immediately? Or is it worth buying IonQ?

The headline numbers, however, masked a familiar strain: the adjusted EBITDA loss widened to $96.8 million in the quarter, building on a full-year 2025 loss of $186.8 million. The reported GAAP net profit came almost entirely from a non-cash warrant revaluation rather than operating income. Investors quickly shifted into a “sell the news” posture.

Part of the premium story now hinges on the SkyWater Technology acquisition. Shareholders approved the deal in May, and both boards have given unanimous backing. The terms call for $15 in cash and $20 in IonQ stock per SkyWater share, with a collar mechanism. Closing is expected in the second or third quarter of 2026. If completed, IonQ would become the only vertically integrated quantum computing company in the U.S.

Valuation remains the central tension. IonQ’s price-to-sales ratio stood at 109 in mid-May, a level that historically has proven unsustainable for early-stage tech companies once it exceeds 30. The company holds $3.1 billion in cash and investments, and 60% of revenue now comes from enterprise customers, with 35% generated internationally across more than 30 countries. Yet insider behavior adds a cautionary note: at IonQ, Rigetti and D-Wave, insiders have been net sellers of stock over the past five years — a sign that management views current valuations as historically rich.

IonQ at a turning point? This analysis reveals what investors need to know now.

Analyst targets vary widely. Wedbush raised its price target to $75, Jefferies cut to $85, and Morgan Stanley held at $48.50 with an equal-weight rating. The consensus average sits near $68 — already below the stock’s current level around $70. Institutional investors own 41.42% of the float, while short interest, despite a 12.47% decline, remains elevated at 20.71% of shares outstanding.

Upcoming catalysts include the Mizuho Global Technology Conference on June 9 in New York, the Rosenblatt Annual Technology Summit on June 10, and IonQ’s annual general meeting on June 16, where shareholders will vote on executive compensation and the appointment of Ernst & Young as auditor. Meanwhile, IBM’s CEO expects to see the first examples of quantum advantage as early as 2026, an event that could re-rate the entire sector regardless of which company delivers the breakthrough.

Ad

IonQ Stock: New Analysis - 3 June

Fresh IonQ information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated IonQ analysis...

en | US46222L1089 | IONQS | boerse | 69475177 |